HS
TSVT

HighVista Strategies’s 2seventy bio TSVT Stock Holding History

HighVista Strategies’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-95,454
Closed -$451K – 165
2024
Q3 		$451K Buy
95,454
+1,954
+2% +$8.81K 0.16% 134
2024
Q2 		$360K Hold
93,500
– – 0.13% 125
2024
Q1 		$500K Buy
+93,500
New +$440K 0.18% 120

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

HighVista Strategies's TSVT Position: Q4 2024 in Review

HighVista Strategies sold out of 2seventy bio (TSVT) in Q4 2024, closing a stake of 95,454 shares — an estimated $451K sold.

HighVista Strategies first reported a position in TSVT in Q1 2024 and held it in 3 quarters. The position peaked at $500K in Q1 2024. 116 funds tracked by Wall St. Rank hold TSVT as of Q4 2024.

  • HighVista Strategies reported no remaining 2seventy bio position as of Q4 2024 after selling out during the quarter.
  • HighVista Strategies sold 95,454 2seventy bio shares in Q4 2024, an estimated $451K.
  • HighVista Strategies first reported a position in 2seventy bio in Q1 2024 and held it in 3 quarters.
  • HighVista Strategies's 2seventy bio position peaked at $500K in Q1 2024.
  • 116 funds tracked by Wall St. Rank held 2seventy bio as of Q4 2024.

Based on HighVista Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.